Perspective Therapeutics CAO granted 90,000 options

Perspective Therapeutics reported that Chief Accounting Officer Jonathan Robert Hunt received a grant of stock options representing the right to buy 90,000 shares, with a grant date of March 2, 2026.

Rhea-AI Filing Summary

Perspective Therapeutics reported that Chief Accounting Officer Jonathan Robert Hunt received a grant of stock options representing the right to buy 90,000 shares, with a grant date of March 2, 2026. These options were approved by the board’s compensation committee as his annual equity award for 2026.

The options have a stated exercise price of $0.0000 per share and vest over four years in 48 substantially equal monthly installments starting one month after the grant date, conditioned on his continued service with the company.

Insider Trade Summary

Grant/Award: 90,000 shares

Grant/Award 1 txn

Insider Hunt Jonathan Robert

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	90,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 90,000 contracts (Direct)

Footnotes (2)

1. F1. The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 4, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026.
2. F2. Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Perspective Therapeutics (CATX) report for Jonathan Robert Hunt?

Perspective Therapeutics reported that Chief Accounting Officer Jonathan Robert Hunt received a grant of stock options for 90,000 shares on March 2, 2026. This derivative award represents his annual equity grant for 2026 and does not involve an open-market stock purchase or sale.

How many stock options did the CATX Chief Accounting Officer receive in this Form 4 filing?

The Chief Accounting Officer received stock options covering 90,000 shares. The options are described as a stock option (right to buy) with a reported exercise price of $0.0000 per share and total post-transaction holdings of 90,000 derivative securities directly owned.

When was Jonathan Robert Hunt’s 2026 equity award approved and granted at Perspective Therapeutics (CATX)?

The option award was approved by the Compensation Committee on February 4, 2026, with a grant date of March 2, 2026. The Form 4 notes this grant represents Jonathan Robert Hunt’s annual equity award for the company’s 2026 compensation cycle.

What are the vesting terms of the 90,000 stock options granted to the CATX Chief Accounting Officer?

The 90,000 stock options vest and become exercisable over four years in 48 substantially equal monthly installments. Vesting begins one month after the March 2, 2026 grant date, and each installment requires Jonathan Robert Hunt’s continued service on the applicable vesting date.

Is the stock option grant to Jonathan Robert Hunt at CATX an open-market transaction?

No, the transaction is classified as a grant or award of derivative securities, not an open-market trade. The Form 4 shows an acquisition code “A” for stock options, with no shares bought or sold in the market and no transaction price beyond the stated exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 04:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hunt Jonathan Robert

(Last) (First) (Middle)

C/O PERSPECTIVE THERAPEUTICS, INC.

2401 ELLIOTT AVENUE, SUITE 320

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Perspective Therapeutics, Inc. [ CATX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$5.35	03/02/2026(1)		A		90,000		(2)	03/02/2036	Common Stock	90,000	$0	90,000	D

Explanation of Responses:

1. The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 4, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026.

2. Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.

	/s/ Jonathan Hunt by Chris Nenno, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.